New approaches and procedures for cancer treatment: Current perspectives
Open accessAbstract
Cancer is a global health problem responsible for one in six deaths worldwide. Treating cancer has been a highly complex process. Conventional treatment approaches, such as surgery, chemotherapy, and radiotherapy, have been in use, while significant advances are being made in recent times, including stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, radionics, chemodynamic therapy, sonodynamic therapy, and ferroptosis-based therapy. Current methods in oncology focus on the development of safe and efficient cancer nanomedicines. Stem cell therapy has brought promising efficacy in regenerating and repairing diseased or damaged tissues by targeting both primary and metastatic cancer foci, and nanoparticles brought new diagnostic and therapeutic options. Targeted therapy possessed breakthrough potential inhibiting the growth and spread of specific cancer cells, causing less damage to healthy cells. Ablation therapy has emerged as a minimally invasive procedure that burns or freezes cancers without the need for open surgery. Natural antioxidants demonstrated potential tracking down free radicals and neutralizing their harmful effects thereby treating or preventing cancer. Several new technologies are currently under research in clinical trials, and some of them have already been approved. This review presented an update on recent advances and breakthroughs in cancer therapies.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
When people cannot change a situation, they accept and tolerate it and regulate emotions, especially the force from action tendencies toward immediate avoidance or weakening of the experience, and do not suffer from performance breakdown.
“when they cannot change the situation, accept and tolerate it and regulate emotions, especially the force resulting from action tendencies in the direction of immediate avoidance or weakening of the experience, and do not suffer from performance breakdown(8).”
From Effectiveness of Mindfulness Training in Emotion Regulation and Distress Tolerance among Breast Cancer Patients (2024) · cites this paper as [8]
The Conventional cancer therapies and Advanced and innovative cancer therapies sections discuss treatments and drug resistance, not how people respond when they cannot change a situation. Searches for acceptance, emotion regulation, avoidance, and performance breakdown found no passage addressing the claim. The indexed passages provide no page numbers. (LLM, conf=0.77)
Experimental — accuracy not yet measuredGenerally, a person is expected to increase distress tolerance by training in mindfulness-based cognitive therapy.
“Generally, a person is expected to increase a meta-emotional structure called distress tolerance by training in mindfulness-based cognitive therapy.”
From Effectiveness of Mindfulness Training in Emotion Regulation and Distress Tolerance among Breast Cancer Patients (2024) · cites this paper as [8]
The Abstract and the sections on conventional and targeted cancer therapies discuss cancer treatments, not mindfulness-based cognitive therapy or distress tolerance (page numbers unavailable). Searches for those terms and for psychological interventions found no passage addressing the claim. (LLM, conf=0.78)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · see citing works
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456 · see citing works
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769 · see citing works
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543 · see citing works
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522 · see citing works
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004 · see citing works
Oxidative stress and cancer: Have we moved forward?
Halliwell, B. (2007) · Biochemical Journal · doi:10.1042/bj20061131 · Cited by 1,302 · see citing works
Targeting the PI3K-Akt pathway in human cancer
Luo, J., Manning, B. D., & Cantley, L. C. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00248-4 · Cited by 1,290 · see citing works
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,254 · see citing works
Mechanisms of Tissue Injury in Cryosurgery
Gage, A. A., & Baust, J. G. (1998) · Cryobiology · doi:10.1006/cryo.1998.2115 · Cited by 1,096 · see citing works
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084 · see citing works
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,070 · see citing works
Konopleva, M. Y., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L. J., Busman, T. A., McKeegan, E. M., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,067 · see citing works
Li, Y., Hermanson, D., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.06.002 · Cited by 986 · see citing works
Chitosan-based formulations for delivery of DNA and siRNA
Mao, S., Sun, W., & Kissel, T. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.08.004 · Cited by 970 · see citing works
Assessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N. E., Sáez, B., Lambea, J., Tres, A., Valladares, M., & González‐Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 932 · see citing works
Improving the efficacy of antibody-based cancer therapies
Carter, P. M. (2001) · Nature reviews. Cancer · doi:10.1038/35101072 · Cited by 833 · see citing works
Innovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 832 · see citing works
Urban-Klein, B., Werth, S., Abuharbeid, S., Czubayko, F., & Aigner, A. M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302425 · Cited by 714 · see citing works
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas‐Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 628 · see citing works
Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment
Chikara, S., Nagaprashantha, L. D., Singhal, J., Horne, D. A., Awasthi, S., & Singhal, S. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.002 · Cited by 561 · see citing works
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M. F., & Arsenian‐Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 554 · see citing works
Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance
Shapira, A., Livney, Y. D., Broxterman, H. J., & Assaraf, Y. G. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.003 · Cited by 509 · see citing works
Recent advances in the development of gene delivery systems.
Sung, Y., & Kim, S. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0156-z · Cited by 458 · see citing works
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435 · see citing works
Natural products for human health: an historical overview of the drug discovery approaches
Bernardini, S., Tiezzi, A., Masci, V. L., & Ovidi, E. (2017) · Natural Product Research · doi:10.1080/14786419.2017.1356838 · Cited by 354 · see citing works
Advancing the field of drug delivery
Moses, M. A., Brem, H., & Langer, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00276-9 · Cited by 344 · see citing works
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y., & Park, T. G. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 339 · see citing works
Knight, S. R., Shaw, C., Pius, R., Drake, T. M., Norman, L., Ademuyiwa, A. O., Adisa, A., Aguilera, M. L., Al‐Saqqa, S. W., Al‐Slaibi, I., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00001-5 · Cited by 330 · see citing works
FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels
Trujillo-Alonso, V., Pratt, E. C., Zong, H., Lara-Martinez, A., Kaittanis, C., Rabie, M. O., Longo, V. A., Becker, M. W., Roboz, G. J., Grimm, J., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0406-1 · Cited by 319 · see citing works
Positron Emission Tomography As an Imaging Biomarker
Weber, W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6068 · Cited by 313 · see citing works
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Dai, H., Wang, Y., Lu, X., & Han, W. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv439 · Cited by 300 · see citing works
Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy
Vakhshiteh, F., Atyabi, F., & Ostad, S. N. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200036 · Cited by 283 · see citing works
(2023) · Advances in pharmacology · doi:10.1016/s1054-3589(23)00038-8 · Cited by 253 · see citing works
Thermal Tumor Ablation in Clinical Use
Brace, C. L. (2011) · IEEE Pulse · doi:10.1109/mpul.2011.942603 · Cited by 252 · see citing works
RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?
Meng, Z., & Lu, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00331 · Cited by 226 · see citing works
Chu, D., Nguyen, T. T., Tien, N. L. B., Khoa, T. D., Jeong, J., Pham, A. G., Thanh, V. V., Truong, D. T., & Dinh, T. C. (2020) · Cells · doi:10.3390/cells9030563 · Cited by 224 · see citing works
p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study
Ahrendt, S. A., Hu, Y. C., Buta, M. R., McDermott, M., Benoit, N. E., Yang, S. C., Wu, L., & Sidransky, D. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.961 · Cited by 222 · see citing works
Delivery systems for siRNA drug development in cancer therapy
Xu, C., & Wang, J. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.08.011 · Cited by 221 · see citing works
Nanodelivery of Natural Antioxidants: An Anti-aging Perspective
Vaiserman, A. M., Koliada, A. K., Zayachkivska, A., & Lushchak, O. V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00447 · Cited by 208 · see citing works
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
Zhao, Z., Zheng, L., Chen, W., Weng, W., Song, J., & Ji, J. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0817-3 · Cited by 177 · see citing works
Fleming, J. B., Shen, G.-L., Holloway, S. E., Davis, M., & Brekken, R. A. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-04-0206 · Cited by 176 · see citing works
Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities
Lin, W., Huang, L., Li, Y., Fang, B., Li, G., Chen, L., & Xu, L. (2019) · BioMed Research International · doi:10.1155/2019/2820853 · Cited by 165 · see citing works
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 154 · see citing works
siRNA based drug design, quality, delivery and clinical translation
Subhan, M. A., & Torchilin, V. P. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102239 · Cited by 152 · see citing works
Singh, S., & Melnik, R. (2020) · Electromagnetic Biology and Medicine · doi:10.1080/15368378.2020.1741383 · Cited by 146 · see citing works
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)
Wagner, M. J., Mitra, R., McArthur, M. J., Baze, W. B., Barnhart, K. F., Wu, S. Y., Rodriguez‐Aguayo, C., Zhang, X., Coleman, R. L., Lopez‐Berestein, G., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0541 · Cited by 131 · see citing works
A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment
El‐Hussein, A., Manoto, S. L., Ombinda-Lemboumba, S. S., et al. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200403144945 · Cited by 125 · see citing works
Antisense RNA gene therapy for studying and modulating biological processes
Weiss, B., Davidkova, G., & Zhou, L.-W. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050296 · Cited by 114 · see citing works
Modulation of the Tumor Microenvironment for Cancer Treatment: A Biomaterials Approach
Adjei, I. M., & Sharma, B. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6010081 · Cited by 112 · see citing works
Effects of quercetin on proliferation and migration of human glioblastoma U251 cells
Liu, Y., Tang, Z., Lin, Y., Qu, X., Lv, W., Wang, G., & Li, C.-L. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.044 · Cited by 111 · see citing works
Yap, T. A., & Workman, P. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134532 · Cited by 104 · see citing works
Genetically modified mesenchymal stromal cells in cancer therapy
Sage, E., Thakrar, R., & Janes, S. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.003 · Cited by 103 · see citing works
Yang, F., SONG, L., Wang, H., Wang, J., Xu, Q., & Xing, N. (2015) · Oncology Reports · doi:10.3892/or.2015.3886 · Cited by 99 · see citing works
Cucurmin, anticancer, & antitumor perspectives: A comprehensive review
Imran, M., Ullah, A., Saeed, F., Nadeem, M., Arshad, M., & Suleria, H. (2018) · Critical reviews in food science and nutrition · doi:10.1080/10408398.2016.1252711 · Cited by 99 · see citing works
Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Räty, J. K., Pikkarainen, J. T., Wirth, T. C., & Ylä‐Herttuala, S. (2008) · Current Molecular Pharmacology · doi:10.2174/1874467210801010013 · Cited by 98 · see citing works
Casper, J., Wolff, D., Knauf, W. U., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3429 · Cited by 95 · see citing works
Cancer Nanomedicine: A New Era of Successful Targeted Therapy
El-Readi, M. Z., & Althubiti, M. (2019) · Journal of Nanomaterials · doi:10.1155/2019/4927312 · Cited by 90 · see citing works
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors
Yakkala, C., Chiang, C. L.-L., Kandalaft, L., Denys, A., & Duran, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02283 · Cited by 88 · see citing works
Sullivan, C., Porter, R. M., Evans, C. H., Ritter, T., Shaw, G., Barry, F., & Murphy, J. M. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt492 · Cited by 82 · see citing works
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference
Charmsaz, S., Collins, D. M., Perry, A. S., & Prencipe, M. (2019) · Cancers · doi:10.3390/cancers11081125 · Cited by 77 · see citing works
A History of Cryosurgery: Its Development and Future
Korpan, N. N. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2006.11.006 · Cited by 68 · see citing works
Mobilization and collection of peripheral blood progenitor cells for transplantation
Reddy, R. L. (2005) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2004.10.007 · Cited by 63 · see citing works
Farooqı, A. A., Qureshi, M. Z., Khalid, S., et al. (2019) · Cancers · doi:10.3390/cancers11040478 · Cited by 63 · see citing works
Kim, H. S., Song, I. H., Kim, J. C., et al. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.003 · Cited by 62 · see citing works
Modifying the tumor microenvironment using nanoparticle therapeutics
Roy, A., & Li, S. (2016) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1406 · Cited by 60 · see citing works
Khalil, C., Moussa, M., Azar, A., Tawk, J., Habbouche, J., Salameh, R., Ibrahim, A., & Alaaeddine, N. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0546-9 · Cited by 57 · see citing works
Ghanghoria, R., Kesharwani, P., Tekade, R. K., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.002 · Cited by 55 · see citing works
Andreozzi, P., Diamanti, E., Py-Daniel, K. R., Cáceres‐Vélez, P. R., Martinelli, C., Πολιτάκος, Ν., Escobar, A., Muzi-Falconi, M., Azevedo, R. B., & Moya, S. E. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b11132 · Cited by 52 · see citing works
Induced Pluripotent Stem Cell-Based Cancer Vaccines
Ouyang, X., Telli, M. L., & Wu, J. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01510 · Cited by 50 · see citing works
Enhanced Anti-Tumor Effects with Microencapsulated c- myc Antisense Oligonucleotide
Putney, S. D., Brown, J. N., Cucco, C., et al. (1999) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1999.9.451 · Cited by 36 · see citing works
Smith, C. E. P., & Prasad, V. K. (2021) · PubMed · Cited by 35 · see citing works
Recent advances in siRNA delivery
Sarısözen, C., Salzano, G., & Torchilin, V. P. (2015) · BioMolecular Concepts · doi:10.1515/bmc-2015-0019 · Cited by 34 · see citing works
Merriel, S. W., Ingle, S. M., May, M., & Martin, R. M. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044420 · Cited by 29 · see citing works
Mylotarg approved for patients with CD33+ acute myeloid leukemia.
Sorokin, P. (2002) · PubMed · Cited by 25 · see citing works
Valter, K., Chen, L., Kruspig, B., Maximchik, P. V., Cui, H., Zhivotovsky, B., & Gogvadze, V. G. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.016 · Cited by 22 · see citing works
Jacobs, S. A. (2007) · PubMed Central · Cited by 20 · see citing works
A Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment
(2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18755992mta1vnjqg3 · Cited by 20 · see citing works
Liu, Y., Cao, C., Yu, Y., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4997 · Cited by 16 · see citing works
Designing antibodies for oncology
Tanner, J. E. (2005) · Cancer and Metastasis Reviews · doi:10.1007/s10555-005-6197-x · Cited by 15 · see citing works
Nanoparticles for Targeted Drug Delivery to Cancer Stem Cells and Tumor
Wang, H., & He, X. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8661-3_6 · Cited by 13 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- [7]Abbas Z Rehman S. An overview of cancer treatment modalities. Neoplasm 2018; 1: 139– 157.
- [14]Mondal J Panigrahi AK Khuda-Bukhsh AR. Conventional chemotherapy: problems and scope for combined therapies with certain herbal products and dietary supplements. Austin J Mol Cell Biol 2014; 1: 10.
- [38]Yadav P. Targeted cancer therapy; researchers reflection. Int Peer-Rev J 2017; 1: 11– 17.
- [54]Cabuy E. Thermal ablation in cancer treatment. Reliab Cancer Ther 2012; 2: 1– 68.
Cited by
Sorted by citations
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443 · see citing works
Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022) · Cancers · doi:10.3390/cancers14194601 · Cited by 55 · see citing works
Wearable Healthcare and Continuous Vital Sign Monitoring with IoT Integration
Taherdoost, H. (2024) · Computers, Materials & Continua · doi:10.32604/cmc.2024.054378 · Cited by 47 · see citing works
Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise
Abd, G. M., Laird, M. C., Ku, J. C., & Li, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1227884 · Cited by 41 · see citing works
Phage therapy in oncology: opportunities for cancer prevention and treatment
Mutalik, V. K., Inman, J. L., Chang, H., Arkin, A., & Mao, J.-H. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.02.001 · Cited by 5 · see citing works
Parsaee, S., Jahani, N., Salehiniya, H., & Raeison, M. (2024) · Journal of Breast Diseases · doi:10.61186/ijbd.17.1.84
- Authors
- Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., Kitui, S. K., & Manyazewal, T.
- Affiliations
- Addis Ababa University (ET)
- Centre for Infectious Disease Research in Zambia (ZM)
- Wachemo University (ET)
- Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
- Corresponding author
- Debela, Dejene Tolossa
- Venue
- SAGE Open Medicine
- Publisher
- SAGE Publications
- Published
- 2021-01
- Volume
- 9
- Pages
- 20503121211034366-20503121211034366
- ISSN
- 2050-3121 (ISSN-L)
- PMC
- PMC8366192
- OpenAlex
- W3190191592
- Cited by
- 1,597
- References
- 83
- Citations by year
- 2026: 250 · 2025: 487 · 2024: 580 · 2023: 234 · 2022: 46
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2024-10-29)
- Open access
- gold
- doi.org
- Licence
- Locations
- SAGE Open Medicine (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advances in Oncology and Radiotherapy
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- cancer therapy, stem cell therapy, targeted therapy, ablation therapy, cancer nanomedicine, nanoparticles, natural antioxidants, radionics, chemodynamic therapy, sonodynamic therapy, minimally invasive cancer therapy, free radicals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
